Literature DB >> 11950712

Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering.

Roberta Baetta1, Marina Camera, Carmen Comparato, Caterina Altana, Michael D Ezekowitz, Elena Tremoli.   

Abstract

The expression of tissue factor (TF), mainly by infiltrated inflammatory cells, has been shown to be responsible for the thrombogenicity associated with atheroma. The contribution of the nonlipid-related effects of statins to the clinical benefits of statin therapy is currently under intense investigation. In this study, we evaluated the ability of fluvastatin to modulate TF expression and macrophage accumulation in rabbit carotid intimal lesions independently of cholesterol lowering. Male rabbits were fed for 30 days a 1% cholesterol-rich diet with or without fluvastatin at 5 mg/kg per day. Two weeks from the start of treatment, a silastic collar was placed around the carotid artery. Fifteen days later, the animals were killed, and carotid segments were excised and processed. The atherogenic diet caused a consistent increase in plasma cholesterol levels (610+/-231 mg/dL versus 50+/-9 mg/dL at baseline), which were not affected by fluvastatin (603+/-248 mg/dL). In the rabbits fed a high cholesterol diet without fluvastatin, an intimal lesion with macrophage accumulation and TF expression was detected. Fluvastatin significantly reduced TF and macrophage content of the lesion (-50% for both). Results indicate that fluvastatin may attenuate the inflammatory and thrombogenic potential of atherosclerotic lesions through a mechanism(s) other than cholesterol reduction, providing new insight regarding the complex mode of action of statins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950712     DOI: 10.1161/01.atv.0000012802.69414.a8

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

Review 1.  Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

Authors:  Kwang Kon Koh; Michael J Quon; Robert S Rosenson; Wook-Jin Chung; Seung Hwan Han
Journal:  Int J Cardiol       Date:  2007-07-20       Impact factor: 4.164

Review 2.  Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Res       Date:  2012-03-22       Impact factor: 3.944

3.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Authors:  A Phillip Owens; Freda H Passam; Silvio Antoniak; Stephanie M Marshall; Allison L McDaniel; Lawrence Rudel; Julie C Williams; Brian K Hubbard; Julie-Ann Dutton; Jianguo Wang; Peter S Tobias; Linda K Curtiss; Alan Daugherty; Daniel Kirchhofer; James P Luyendyk; Patrick M Moriarty; Shanmugam Nagarajan; Barbara C Furie; Bruce Furie; Douglas G Johns; Ryan E Temel; Nigel Mackman
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.

Authors:  Aneel A Ashrani; Michel K Barsoum; Daniel J Crusan; Tanya M Petterson; Kent R Bailey; John A Heit
Journal:  Thromb Res       Date:  2015-04-11       Impact factor: 3.944

5.  Improved animal models for testing gene therapy for atherosclerosis.

Authors:  Liang Du; Jingwan Zhang; Guido R Y De Meyer; Rowan Flynn; David A Dichek
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

Review 6.  Role of tissue factor in atherothrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

7.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

Review 8.  Fluvastatin: clinical and safety profile.

Authors:  Alberto Corsini; Terry A Jacobson; Christie M Ballantyne
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda
Journal:  Exp Clin Cardiol       Date:  2005

Review 10.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.